Resumption of anticoagulant therapy after major bleeding and recurrence of hemorrhagic complications in patients with atrial fibrillation with a high risk of stroke and thromboembolism (based on the results of 20 years of observation)
- Authors: Mironova (Staroverova) A.I.1, Panchenko E.P.1, Kropacheva E.S.1, Zemlyanskaya O.A.1
-
Affiliations:
- Myasnikov Institute of Clinical Cardiology, National Medical Research Center for Cardiology
- Issue: Vol 92, No 9 (2020)
- Pages: 15-23
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/46846
- DOI: https://doi.org/10.26442/00403660.2020.09.000655
- ID: 46846
Cite item
Full Text
Abstract
Aim. To analyze the frequency of resumption of anticoagulant therapy (ACT) after major and clinically significant bleeding among AF patients who received oral anticoagulants and were observed in the Department of clinical problems of atherothrombosis from 1999 to 2019 within the retro-prospective register «Regata-2», and to search for clinical factors associated with recurrence of hemorrhagic complications among patients who resumed anticoagulant therapy after a bleeding episode.
Materials and methods. In cohort study of patients with high-risk AF with absolute indications for ACT we enrolled 290 AF patients (130 women and 160 men) aged 32 to 85 years (the average age was 65.18±8.89 years). During the follow-up period, 92 patients developed hemorrhagic complications, and 73 of them resumed ACT. 35 of the 73 patients who resumed ACT developed a relapse of major/clinically significant bleeding.
Results. The frequency of resuming ACT after the first hemorrhagic complication increased over time from 75% in the period from 1999–2003 to 90% in the period 2015–2019. We were not able to establish an exact relationship between the presence of concomitant pathology and the decision to resume the ACT after bleeding. The only reliable reason for refusing to resume the ACT was the patient’s categorical reluctance. Among patients who had recurrent hemorrhagic complications, the total score on the Charleson comorbidity scale was significantly higher (4.23±2.01 vs 3.52±1.43; p=0.0425). Patients with recurrent bleeding were significantly more likely to suffer from CKD with a decrease in GFR less than 60 ml/min/1.73 sq. m, and also had a history of erosive and ulcerative lesions of the gastrointestinal tract. There was also a significant Association of recurrent bleeding with the use of proton pump inhibitors. Subgroups of patients who switched from warfarin to taking direct oral anticoagulants after the first bleeding and subsequent recurrent bleeding did not differ in basic clinical characteristics from patients without bleeding after changing the anticoagulant. According to multiple regression analysis, NSAIDs showed a tendency to develop a relapse of B/C bleeding on the background of direct oral anticoagulants in patients who underwent GO on the background of warfarin therapy (b=0.4524, p=0.0530).
Conclusion. During the 20-year follow-up, the frequency of all major and clinically significant bleeding was 2.6/100 patients-years, the frequency of first bleeding was 5.86/100 patients-years, while the frequency of repeated hemorrhagic complications was 7.06/100 patients-years. Patients with a high thromboembolic risk should receive anticoagulants, provided that the modifiable risk factors for bleeding are carefully corrected.
Full Text
##article.viewOnOriginalSite##About the authors
A. I. Mironova (Staroverova)
Myasnikov Institute of Clinical Cardiology, National Medical Research Center for Cardiology
Author for correspondence.
Email: adiy-sun@mail.ru
ORCID iD: 0000-0001-5788-5880
клинический ординатор
Russian Federation, MoscowE. P. Panchenko
Myasnikov Institute of Clinical Cardiology, National Medical Research Center for Cardiology
Email: adiy-sun@mail.ru
ORCID iD: 0000-0002-1174-2574
д.м.н., проф., рук. отд. клинических проблем атеротромбоза
Russian Federation, MoscowE. S. Kropacheva
Myasnikov Institute of Clinical Cardiology, National Medical Research Center for Cardiology
Email: adiy-sun@mail.ru
ORCID iD: 0000-0002-3092-8593
к.м.н., ст. науч. сотр. отд. клинических проблем атеротромбоза
Russian Federation, MoscowO. A. Zemlyanskaya
Myasnikov Institute of Clinical Cardiology, National Medical Research Center for Cardiology
Email: adiy-sun@mail.ru
ORCID iD: 0000-0003-4035-2943
к.м.н., мл. науч. сотр. отд. клинических проблем атеротромбоза
Russian Federation, MoscowReferences
- Halvorsen S, Storey RF, Rocca B, et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2017;38:1455-62. doi: 10.1093/eurheartj/ehw454
- Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). AHJ. 2012;163(1):13-9. doi: 10.1016/j.ahj.2011.09.011
- Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955-62. doi: 10.1016/S0140-6736(13)62343-0
- Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124:955-62. doi: 10.1182/blood-2014-03-563577
- Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. Int Emerg Med. 2018;13:1051-8. doi: 10.1007/s11739-018-1877-z
- Lip G, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a «real world» nationwide cohort study. Thromb Haemost. 2011. doi: 10.1160/TH11-05-0364
- Little D, Chai-Adisaksopha C, Hillis C, et al. Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: A systematic review and meta-analysis. Thromb Res. 2019;175:102-9. doi: 10.1016/j.thromres.2019.01.020
- Cameron C, Coyle D, Richter T, et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open. 2014;4(6):e004301. doi: 10.1136/bmjopen-2013-004301
- Pasquini M, Charidimou A, van Asch CJ, et al. Variation in Restarting Antithrombotic Drugs at Hospital Discharge After Intracerebral Hemorrhage. Stroke. 2014;45(9):2643-8. doi: 10.1161/strokeaha.114.006202
- Kyohei M, Takatsugu Y, Hitoshi A, et al. Difference between the Upper and the Lower Gastrointestinal Bleeding in Patients Taking Nonvitamin K Oral Anticoagulants. BioMed Res Int. 2018;24:1-5. doi: 10.1155/2018/7123607
- Землянская О.А., Кропачева Е.С., Добровольский А.Б., Панчен- ко Е.П. Функция почек у больных, длительно принимающих варфарин (5-летнее проспективное наблюдение). Терапевтический архив. 2017;89(9):78-86 [Zemlyanskaya ОА, Kropacheva ES, Dobrovolsky AB, Panchenko EP. Renal function in patients taking long-term warfarin (5-year prospective follow-up). Therapeutic Archive. 2017;89(9):78-86 (In Russ.)]. doi: 10.17116/terarkh201789978-86
- Sciascia S, Radin M, Schreiber K, et al. Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. Int Emerg Med. 2017;12(8):1101-8. doi: 10.1007/s11739-017-1753-2
- O’Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleedingrisk in atrial fibrillation. Eur Heart J. 2015;36(46):3258-64. doi: 10.1093/eurheartj/ehv476
- Kumar S, Lim E, Covic A, et al. Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;74(17):2204-15. doi: 10.1016/j.jacc.2019.08.1031
- Кропачева Е.С., Землянская О.А., Панченко Е.П. и др. Безопасность длительной терапии варфарином: частота кровотечений и клинические предикторы их развития (результаты проспективного 15-летнего наблюдения). Атеротромбоз. 2017;1 [Kropacheva ES, Zemlyanskaya ОА, Panchenko EP. Long-term therapy safety warfarine: bleeding rate and clinical predictors of their development. Aterotromboz. 2017;1 (In Russ.)]. doi: 10.21518/2307-1109-2017-1-28-32
- Al-Shahi Salman R, Dennis M, Sandercock P, et al. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet. 2019;393(10191):2613-23. doi: 10.1016/S0140-6736(19)30840-2
- Schjerning Olsen AM, McGettigan P, Gerds TA, et al. Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study. Eur Heart J Cardiovasc Pharmacother. 2019. pii: pvz069. doi: 10.1093/ehjcvp/pvz069
- Dalgaard F, Mulder H, Wojdyla DM, et al. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. Circulation. 2020;141(1):10-20. doi: 10.1161/CIRCULATIONAHA.119.041296
- Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57(2):173-80. doi: 10.1016/j.jacc. 2010.09.024
- Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395-401. doi: 10.1016/j.jacc.2011.03.031
- Gage BF, Yan Y, Milligan PE et al. Clinical classification schemes for predicting hemorrhage:results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713-9. doi: 10.1016/j.ahj.2005.04.017
- Olesen JB, Lip GY, Hansen PR, et al. Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two establishedbleeding prediction schemes in a nationwide cohort. J Thromb Haemost. 2011;9(8):1460-7. doi: 10.1111/j.1538-7836.2011.04378.x
- Hijazi Z, Oldgren J, Lindbäck J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016;387(10035):2302-11. doi: 10.1016/s0140-6736(16)00741-8
- Berg DD, Ruff CT, Jarolim P, et al. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. Circulation. 2019;139(6):760-71. doi: 10.1161/CIRCULATIONAHA.118.038312
- Hijazi Z, Oldgren J, Siegbahn A, et al Biomarkers in atrial fi brillation: a clinical review. Eur Heart J. 2013;34:1475-80. doi: 10.1093/eurheartj/eht024
- Aulin J, Siegbahn A, Hijazi Z, et al. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J. 2015;170:1151-60. doi: 10.1016/j.ahj.2015.09.018
- Christersson C, Wallentin L, Andersson U, et al. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial. J Thromb Haemost. 2014;12:1401-12. doi: 10.1111/jth.12638
- Hijazi Z, Aulin J, Andersson U, et al. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart. 2016;102:508-17. doi: 10.1136/heartjnl-2015-308887
- Wallentin L, Hijazi Z, Andersson U, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014;130(21):1847-58. doi: 10.1161/CIRCULATIONAHA.114.011204
- Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, et al. Long-term bleeding risk prediction in «real world» patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project. Thromb Haemost. 2017;117(10):1848-58. doi: 10.1160/TH17-07-0478